ExpreS2ion Biotechnologies is a world leading contract research organisation (CRO) within production in Drosophila Schneider-2 (S2) cells.

For 15 years we have developed, and actively used our proprietary and complete S2 recombinant protein technology ExpreS2.

We have in-depth practical experience with this non-viral Drosophila S2 expression technology for the production of recombinant proteins for research, preclinical development and for use in clinical trials.

Our solutions:

Products

Services

Customers and collaborating partners

spacer

About

ExpreS2ion Biotechnologies is a world leading CRO biotech company

Our company has a proprietary and complete S2 recombinant protein technology base – ExpreS2, which was developed over ten years at Pharmexa A/S. We have in-depth practical experience with the non-viral Drosophila S2 expression technology for the production of recombinant proteins for preclinical development and for use in clinical trials.

Contribution to Malaria Vaccines/Research

By leveraging our ability to express malaria parasite proteins with ExpreS2 a cGMP-compatible system, we have enabled progress of malaria vaccine candidates into clinical research. ExpreS2ion Biotechnologies is working with top academic teams to advance vaccines directed at different malaria stages of infection: blood stage malaria and pregnancy malaria.

Solutions

Services, Custom Proteins

“Challenging proteins made easy”

The ExpreS2 system, based on Drosophila S2 cell expression can solve your “protein dead-ends” by providing an alternative, cGMP-compatible expression system.
When to choose the S2 expression system:

  • Secreted or secretable proteins
  • Low/non-expressing proteins in HEK293 or BEVS
  • Issues with protein cleavage during production
  • Heterodimers or further multimeric proteins
  • If variable glycosylation is an issue
  • If you need a cGMP-compatible system

ExpreS2ion Biotechnologies specializes in establishment of high-producing cell lines together with upstream process development and working with customers to solve technical problems in molecular biology, protein expression or other issues relating to S2 cells. S2 related reagents are also available.

NEWS / EVENTS

Latest news

October 2014 : ExpreS2ion® Biotechnologies is sponsoring the World Vaccine Conference, Brussels, Belgium, October 13th-15th.

October 2014 : ExpreS2ion® Biotechnologies is presenting at the Epic Biotech, the European Partnering and Investment Conference, London, UK, October 2nd.

September 2014 : ExpreS2ion® Biotechnologies is sponsoring the session “Current challenges in protein production in academia & industry: membrane proteins, protein complexes & biologics”.

Publications
  • "Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies" enabled by the ExpreS2 technology platform: Nature (17 August 2014), doi:10.1038/nature13715 Read the abstract here

  • The external domain of rat ErbB-2 conjugated with a tetanus toxin Th-cell epitope were produced in Drosophila melanogaster S2 insect cell cultures, in the recent publication: Vaccine. 2014 Feb 12;32(8):1012-8. doi: 10.1016/j.vaccine.2013.10.077. Epub 2013 Nov 11

  • Comparison of prophylactic and therapeutic immunisation with an ErbB-2 (HER2) fusion protein and immunoglobulin V-gene repertoire analysis in a transgenic mouse model of spontaneous breast cancer. Mukhopadhyay A, Dyring C, Stott DI. Read the abstract here

  • ExpreS2ion Biotechnologies: Agern Allé 1, DK-2970 Horsholm, Denmark E-mail: info@expres2ionbio.com Phone: +45 4166 6121